OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle
S J
SJ
Department of Surgery, University of Wisconsin Hospital and Clinics, Madison.
Pirsch
J D
JD
Groshek
M
M
Reed
A
A
D'Alessandro
A M
AM
Kalayoglu
M
M
Belzer
F O
FO
Sollinger
H W
HW
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D017252:CD3 Complex; D003586:Cytomegalovirus Infections / Q000150:complications; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3; D009894:Opportunistic Infections / Q000150:complications; D016035:Pancreas Transplantation / Q000379:methods*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000961:Antilymphocyte Serum; D017252:CD3 Complex; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell